Press Releases

If you want to subscribe to our press releases please go to the Cision site where it is possible to subscribe.

Note: After January 21, 2020, all press releases are published in English as original language.

Warrants of series TO5 were subscribed to approximately 97.4 percent and ExpreS2ion receives approximately SEK 44.3 million

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SINGAPORE, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.…

Read more

Last day of trading in warrants of series TO5 is September 16, 2021

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

ExpreS2ion announces TO5 warrant exercise price and start of subscription period

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

ExpreS2ion will participate in key investor events in September 2021

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB (“ExpreS2ion") will participate and hold presentations at key investor events in September. These include events hosted by LSX Leaders, Aktiespararna, Økonomisk Ugebrev and Dansk Aktionærforening.

Read more

Pareto Securities and Analysguiden publish research reports with increased price targets of SEK 68 and SEK 55, respectively

Non-regulatory pressrelease

Hørsholm, Denmark, August 25, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have updated their respective research reports on ExpreS2ion in August. Pareto upheld its ‘buy’ rating with a target price of SEK 68 per share, while Analysguiden has set a new fair value of SEK…

Read more

The ABNCoV2 COVID-19 vaccine program receives up to DKK 800 million from the Danish Ministry of Health

Regulatory pressrelease

Hørsholm, Denmark, August 23, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Bavarian Nordic, the exclusive licensee of the ABNCoV2 COVID-19 vaccine, will receive up to DKK 800 million in funding from the Danish Ministry of Health for a Phase III trial to confirm safety and demonstrate efficacy as a…

Read more

ExpreS2ion’s Board and Management committed to fully exercise their TO5 warrants

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

COVID-19 Phase II clinical trial initiated to evaluate ABNCoV2 as a booster vaccine

Regulatory pressrelease

Hørsholm, Denmark, August 23, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a Phase II clinical trial to evaluate the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been initiated by Bavarian Nordic. The trial will investigate the potential of ABNCoV2 as a booster vaccine for individuals with previous…

Read more

Correction: ExpreS2ion announces financial results for the second quarter of 2021

Regulatory pressrelease

Hørsholm, Denmark, August 19, 2021 – This morning ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announced its second quarter financial results for 2021. Some figures were reported incorrectly, specifically the operating income and H1 2020 earnings per share figures reported below in the press release, which are now highlighted in bold. These figures were also incorrect on…

Read more

ExpreS2ion announces financial results for the second quarter of 2021

Regulatory pressrelease

Hørsholm, Denmark, August 19, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its second quarter financial results for 2021. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion management will present the Q2 2021 interim report via webcast on Thursday, August 19, 2021

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB (“ExpreS2ion") will present its second quarter 2021 report via a live virtual webcast hosted by HC Andersen Capital on August 19[th], 2021, at 11-11.30hrs.

Read more

Positive safety and efficacy outcome of the COVID-19 clinical Phase I/II study for the ABNCoV2 vaccine

Regulatory pressrelease

Hørsholm, Denmark, August 09, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that COUGH-1, the COVID-19 Phase I/II clinical trial to evaluate the ABNCoV2 vaccine, as headline results has met its safety and efficacy endpoints with excellent virus neutralization levels of up to 12 times higher compared to the levels achieved…

Read more

Update on a new clinical Phase Ib trial for the RH5.1 blood-stage malaria vaccine

Non-regulatory pressrelease

Hørsholm, Denmark, July 21, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that University of Oxford has initiated the VAC080-study, a Phase Ib clinical trial to assess the safety and immunogenicity of the blood-stage Plasmodium falciparum malaria vaccine candidate RH5.1/Matrix-M in adults and infants living in Tanzania.

Read more

ExpreS2ion publishes video from company presentation at a Nordic investor event

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen at the LifeSci Advisors Nordic Biotech Summit investor event on June 29, 2021 is now available on the company’s Vimeo channel.

Read more

Pareto Securities AS initiates equity research coverage of ExpreS2ion with a Buy rating and target price of 60 SEK per share

Non-regulatory pressrelease

Hørsholm, Denmark, June 24, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Pareto Securities AS has published an equity research initiation report on ExpreS2ion. They initate coverage with a Buy rating and a target price of 60 SEK per share.

Read more

ExpreS2ion will participate in key investor events in June 2021

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB (“ExpreS2ion") will participate and hold presentations at key investor events in June, all of which will be held digitally. These include HC Andersen Capital’s Life Science Seminar (June 16), and LifeSci Advisors Nordic Biotech Summit (June 29).

Read more

Announcement from ExpreS2ion's annual general meeting

Regulatory pressrelease

The annual general meeting 2021 ("AGM") of ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") was held today on 26 May 2021 and the following resolutions were passed by the meeting. Due to the ongoing corona pandemic, the AGM was carried out through postal voting only, without physical presence.

Read more

ExpreS2ion Announces Financial Results for the First Quarter of 2021

Regulatory pressrelease

Hørsholm, Denmark, May 19, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its first quarter financial results for 2021. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion management will present the Q1 2021 interim report via webcast on Wednesday, May 19, 2021

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB (“ExpreS2ion") will present its first quarter 2021 report via a live virtual webcast hosted by HC Andersen Capital on May 19th, 2021, at 12-12.30hrs.

Read more

Lead candidate selected in ExpreS2ion’s HER2-cVLP breast cancer vaccine project

Regulatory pressrelease

Hørsholm, Denmark, May 11, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces the selection of its lead candidate HER2-cVLP breast cancer vaccine. The project runs according to plan.

Read more

ExpreS2ion - Annual report for 2020 published

Regulatory pressrelease

Hørsholm, Denmark, May 05, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company's annual report for the financial year 2020 is published. The annual report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com).

Read more

Warrants of series TO4 were subscribed to approximately 97.6 percent and ExpreS2ion receives approximately SEK 39.0 million

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES Hørsholm,…

Read more

ExpreS2ion appoints new Vice President, Business Development

Non-regulatory pressrelease

Hørsholm, Denmark, April 26, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby announces that it has appointed Mr. Eske Rygaard-Hjalsted as new Vice President, Business Development. Mr. Rygaard-Hjalsted brings more than 25 years of sales, marketing, and business development experience and will be focused on growing the Company’s commercial foothold, both with…

Read more

Proposal for election of two new members of the Board of Directors

Regulatory pressrelease

Hørsholm, Denmark, April 26, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Gitte L. Pedersen does not seek re-election to the Board of Directors at the forthcoming Annual General Meeting on May 26, 2021, and that two new members, Karin Garre and Sara Sande, are proposed for election. Thus, it is proposed to…

Read more

Notice of Annual General Meeting in ExpreS2ion Biotech Holding AB

Regulatory pressrelease

The shareholders of ExpreS2ion Biotech Holding AB, reg. no. 559033-3729, (the "Company"), are hereby convened to the annual general meeting to be held on Wednesday 26 May 2021.

Read more

Analysguiden announces new research report with the target price for ExpreS2ion increased to 49 SEK per share

Non-regulatory pressrelease

Hørsholm, Denmark, April 22, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Aktiespararnars’ Analysguiden has published an updated equity research report on ExpreS2ion. The updated sum-of-the-parts valuation base case increases to 49 SEK per share.

Read more

Publication of clinical Phase I/IIa data in the RH5 blood-stage malaria vaccine

Non-regulatory pressrelease

Hørsholm, Denmark, April 21, 2021 – ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) and its protein production platform ExpreS2™ have contributed to a scientific article published in the journal Med. The article highlights the outcome of the VAC063-study, a Phase I/IIa clinical trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium falciparum malaria vaccine candidate…

Read more

Last day of trading in warrants of series T04 is April 22, 2021

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

Interim safety update on COUGH-1, the COVID-19 clinical phase I/II study for the ABNCoV2 vaccine

Regulatory pressrelease

Hørsholm, Denmark, April 12, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the first group of volunteers in the clinical Phase I/II study, COUGH-1, have been satisfactorily administered with the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine. The clinical study runs as planned with no untoward safety signal in…

Read more

ExpreS2ion announces T04 warrant exercise price, start of subscription period and Board and Executive Management commitment to fully exercise their T04 warrant holdings

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

ExpreS2ion’s platform (ExpreS2) featured in Viruses article on O-glycosylation on SARS-CoV-2 spike protein

Non-regulatory pressrelease

ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) and its protein production platform ExpreS2™ have contributed to a scientific article published in the journal Viruses. The article describes the site-specific O-glycosylation analysis of SARS-CoV-2 spike protein produced in insect and human cells.

Read more

ExpreS2ion updates on its pipeline outlook, including for COVID-19 and HER2 breast cancer projects

Regulatory pressrelease

Hørsholm, Denmark, March 16, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today presents an updated outlook for its pipeline development projects, including the ABNCoV2 COVID-19 vaccine and its ES2B-C001 HER2-cVLP breast cancer vaccine. The update is published ahead of a digital company presentation to be held today at 11.00 CET, during…

Read more

Approval and initiation of the COVID-19 clinical phase I/II study for the ABNCoV2 vaccine

Regulatory pressrelease

Hørsholm, Denmark, March 8, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the clinical trial application (CTA) for a clinical phase I/II study for the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been approved by the Central Committee on Research Involving Human Subjects (CCMO) in the Netherlands. The…

Read more

ExpreS2ion will participate at key industry and investor events in March 2021

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in March, all of which will be held digitally. These include Aktiespararna’s Aktiedagen (March 16), the St. Gallen International Breast Cancer Conference (March 17-21), and BIO-Europe Spring (March 22-25).

Read more

ExpreS2ion Announces 2020 Fourth Quarter and Full-Year Results

Regulatory pressrelease

Hørsholm, Denmark, February 25, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its full-year financial results for 2020 and the fourth quarter of 2020. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion and University of Bologna announce research collaboration to test HER2-cVLP in state-of-the-art breast cancer mice models

Regulatory pressrelease

Hørsholm, Denmark, February 23, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") and the University of Bologna (“UniBo”) announce a research collaboration agreement (“Agreement”) which covers testing of the novel HER2-cVLP breast cancer vaccine program, including the selected lead candidate ES2B-C001, in proprietary state-of-the-art breast cancer mice models. The collaboration follows the…

Read more

ExpreS2ion’s CEO in interview on achievements in 2020 and the company’s outlook for 2021

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) publishes an interview with the company’s CEO Bent Frandsen, in which he sums up the company’s achievements in 2021 and the outlook for the rest of 2021 and beyond. This includes discussing the status of the ABNCoV2 COVID-19 vaccine program and the recently in-licensed ES2B-C001 HER2 breast cancer vaccine project.

Read more

ExpreS2ion granted exclusive global license for HER2-cVLP breast cancer vaccine programme from AdaptVac

Regulatory pressrelease

Hørsholm, Denmark, February 2, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the company has today exercised its option to license a unique breast cancer vaccine by signing a final Patent License Agreement (“the Agreement”) with AdaptVac ApS (“AdaptVac”). ExpreS2ion is granted an exclusive global license to a preclinical-stage novel…

Read more

Analysguiden announces new research report with the target price for ExpreS2ion at 24 SEK per share

Non-regulatory pressrelease

Hørsholm, Denmark, January 27, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Aktiespararnars’ Analysguiden has published an updated equity research report on ExpreS2ion. The updated sum-of-the-parts valuation base case remains at 24 SEK per share.

Read more

Strong preclinical immunization data for the ABNCoV2 cVLP-based COVID-19 vaccine published in Nature Communications

Non-regulatory pressrelease

Today, ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces the publication of strong virus neutralization properties in animal proof-of-concept data for ABNCoV2, a unique capsid virus like particle (cVLP) based COVID-19 vaccine coated with ExpreS2-made SARS-CoV-2 antigens, in the esteemed scientific journal Nature Communications. The ABNCoV2 COVID-19 vaccine is the result…

Read more

ExpreS2ion strengthens its organization to further accelerate its pipeline project development

Regulatory pressrelease

Hørsholm, Denmark, January 11, 2021 – ExpreS2ion Biotech Holding AB hereby announces that its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is reorganizing the company’s top management to reflect its increased strategic focus on pipeline development. Several appointments within research and development will ensure the advancement of ExpreS2ion’s development projects towards clinical investigations, with the first fully controlled…

Read more

ExpreS2ion announces submission of the COUGH-1 clinical trial application by the Prevent-nCoV consortium and Bavarian Nordic to review ABNCoV2

Regulatory pressrelease

Hørsholm, Denmark, January 8, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the clinical trial application (CTA) for a clinical Phase I/II study for the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been submitted to the Central Committee on Research Involving Human Subjects (CCMO) in the Netherlands. The…

Read more

ExpreS2ion publishes filmed scientific interview on the cVLP COVID-19 vaccine development

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed scientific talk on the development of the cVLP COVID-19 vaccine has been published on the company’s website. The video features Dr. Max M Søgaard from ExpreS2ion and Dr. Ali Salanti from ExpreS2ion’s joint venture and development partner AdaptVac.

Read more

ExpreS2ion carries out new share issue for loan conversion

Regulatory pressrelease

Hørsholm, Denmark, November 27, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that SEK 3.5 million (excluding accrued interest) of the loan provided by Modelio Equity AB (https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-last-part-of-loan-conversion-and-new-loan-facility,c3103406) will be set-off against 331,816 new shares at a price of SEK 10.548 per share (corresponding to a 10 percent discount to the volume weighted average share…

Read more

ExpreS2ion announces interim results for the first nine months of 2020

Regulatory pressrelease

Hørsholm, Denmark, November 19, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its interim financial results for the first nine months of 2020 and the third quarter of 2020. The Interim Report (Q3) is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion announces successful manufacturing of the cVLP COVID-19 vaccine and further positive updates

Regulatory pressrelease

Hørsholm, Denmark, November 16, 2020 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the capsid virus like particle (cVLP) based COVID-19 vaccine, which is licensed to Bavarian Nordic, has been successfully manufactured with a full batch release to follow after final quality analysis. The project remains on track for presenting initial…

Read more

First day of trading in warrants of series TO4 and TO5

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

Last day of trading in paid subscribed units (Sw. BTU)

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

ExpreS2ion publishes video from COVID-19-focused company presentation at Japanese event

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation with CEO Bent U. Frandsen at a digital event in Japan, hosted by the Royal Danish Embassy in Tokyo and Healthcare Denmark, has been published on the company’s website.

Read more

ExpreS2ion publishes video from company presentation at a Danish investor event

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen at a Danish investor event on October 21, 2020 has been published on the company’s website.

Read more

ExpreS2ion’s rights issue oversubscribed

Regulatory pressrelease

THIS PRESS RELEASE IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION…

Read more

Last day for subscription in the ongoing rights issue is October 19, 2020

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

ExpreS2ion publishes prospectus in connection with capital raise of up to SEK 216 million

Regulatory pressrelease

THIS PRESS RELEASE IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION…

Read more

ExpreS2ion launches a new company website with increased focus on pipeline project development

Non-regulatory pressrelease

Hørsholm, Denmark, September 29, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces the launch of a significantly upgraded company website. The new website has a stronger focus on ExpreS2ion’s novel technology platforms and the company’s pipeline project development. It also introduces a separate investor site for improved communication with shareholders, potential investors and other…

Read more

ExpreS2ion and Attana have signed a Development and Supply Agreement

Regulatory pressrelease

Hørsholm, Denmark, September 24, 2020 – ExpreS2ion Biotech Holding AB hereby announces that its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") and the biotech tools company Attana AB (“Attana”) have today signed a heads of terms agreement regarding the development and supply of novel ExpreS2ion proteins to Attana. The first target protein will be the ExpreS2ion-produced SARS-CoV-2…

Read more

Announcement from the extra general meeting in ExpreS2ion Biotech Holding

Regulatory pressrelease

The extra general meeting in ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") was held today on 23 September 2020 and the following resolutions were passed by the meeting.

Read more

ExpreS2ion will present its technology platform and pipeline at several key events in September and October 2020

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate at several key events in September and October, including Aktiespararna’s Aktiedagen, September 15 in Lund, Sweden, World Vaccine Congress Washington Virtual, September 28–October 1, and World Vaccine Congress Europe Digital Event, October 19–21.

Read more

Analysguiden raises its target price for ExpreS2ion to 24 SEK per share

Non-regulatory pressrelease

Hørsholm, Denmark, September 3, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Aktiespararnars’ Analysguiden has published an updated equity research report on ExpreS2ion. The updated sum-of-the-parts valuation base case is raised to 24 SEK per share after the completion of the proposed rights issue in October 2020 at 12 SEK per share.

Read more

Notice to Extra General Meeting in ExpreS[2]ion Biotech Holding AB (publ)

Regulatory pressrelease

The shareholders of ExpreS[2]ion Biotech Holding AB, reg. no. 559033-3729, (the "Company"), are hereby convened to the extra general meeting to be held on Wednesday 23 September 2020, at 10.00 at meeting room Penthouse at Mindpark, Bredgatan 11 in Helsingborg. This is an unofficial translation of a notice to the Annual General Meeting in ExpreS[2]ion…

Read more

ExpreS2ion announces up to SEK 216 million capital raise through a fully guaranteed rights issue to finance ground breaking vaccine and immunotherapy pipeline

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. INSIDE…

Read more

ExpreS2ion – Half-year report for 2020 published

Regulatory pressrelease

Hørsholm, Denmark, August 20, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company's half-year report for 2020 is published. The half-year report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion provides update on its expectations to the COVID-19 vaccine program prior to the Q2 2020 report

Regulatory pressrelease

Hørsholm, Denmark, August 19, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby updates the market on its expectations to the development timelines of the COVID-19 vaccine prior to the release of the Company’s Q2 2002 report. The Company now expects the phase III trials to commence as soon as the first half…

Read more

ExpreS2ion appoints new CFO

Non-regulatory pressrelease

Hørsholm, Denmark, August 18, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby announces that it has appointed Mr. Keith Alexander as new Chief Financial Officer (CFO). Mr. Alexander brings more than 20 years of corporate banking and strategy consulting experience and will initially be focused on strengthening the Company’s financial strategies and…

Read more

ExpreS2ion provides update on anticipated development of the breast cancer vaccine candidate AV001, including a probable change in its ownership stake in AdaptVac

Regulatory pressrelease

Hørsholm, Denmark, August 18, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby announces that ExpreS2ion wishes to exercise the option to inlicense AV001 before it expires on February 26, 2021. The exercise of the option is subject to the Company obtaining the necessary financing to fund the exercise of the option and…

Read more

ExpreS2ion announces exercise of 2017 warrant program

Non-regulatory pressrelease

Hørsholm, Denmark, August 3, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or “the Company”) today announces that all warrants held by employees and Board members under the 2017 Warrant Program, established in April 2017, have been fully exercised. In total, 436,200 warrants were exercised, providing ExpreS2ion SEK 2,656,632. The exercise has increased the number of shares…

Read more

ExpreS2ion’s joint venture AdaptVac signs Final License Agreement with Bavarian Nordic on COVID-19 Vaccine

Regulatory pressrelease

Hørsholm, Denmark, July 22, 2020 – ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion”) hereby announces that its joint venture AdaptVac has entered into a final license agreement with Bavarian Nordic A/S (“Bavarian Nordic”), to license the proprietary capsid virus like particle (cVLP) based SARS-CoV-2 subunit vaccine. Under the terms of the agreement, Bavarian Nordic will make an…

Read more

Strong Proof-of-Concept for cross-strain protective flu cVLP vaccine further strengthens confidence in Coronavirus vaccine

Non-regulatory pressrelease

Hørsholm, Denmark, July 17, 2020 – ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that AdaptVac has announced publication of a paper in the journal Vaccines, where its broadly protective Flu cVLP vaccine induced a more potent, long-lasting immune response and was able to protect mice against both homologous and heterologous H1N1 influenza challenge, even after a single…

Read more

ExpreS2ion’s platform to be used in a novel Zika vaccine candidate

Non-regulatory pressrelease

Hørsholm, Denmark, July 14, 2020 – ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that its ExpreS2[ ]platform will be used in the production of the novel Zika-HX vaccine candidate that is being developed by Excivion Ltd., a UK-based biotechnology company. The manufacturing of the Zika-HX vaccine will be conducted together with CPI, a British independent technology innovation…

Read more

ExpreS2ion provides update on negotiations with Bavarian Nordic and progress towards clinical Phase I/IIa trial

Regulatory pressrelease

Hørsholm, Denmark, July 08, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the cVLP COVID-19 vaccine license agreement negotiation between its joint venture AdaptVac and Bavarian Nordic is expected to continue beyond the previously announced two months’ time frame. The timeline of the already fully funded Phase I/IIa trial is not affected. Process…

Read more

ExpreS2ion announces that the cVLP COVID-19 vaccine shows strong virus neutralization properties in animal proof-of-concept data

Regulatory pressrelease

Hørsholm, Denmark, June 09, 2020 – ExpreS[2]ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the capsid virus-like particle (cVLP) COVID-19 vaccine being developed by ExpreS2ion and its joint venture AdaptVac has demonstrated excellent COVID-19 immunization with very high level of SARS-CoV-2 virus neutralization in a mice model, thus reaching an important pre-clinical milestone ahead of…

Read more

Communique from the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)

Regulatory pressrelease

Today, on May 26[th], 2020, the Annual General Meeting (“AGM”) was held in ExpreS2ion Biotech Holding AB (“ExpreS2ion”). Below follows a summary of the resolutions. The resolutions were passed with the required majority.

Read more

ExpreS2ion – Interim report for the first quarter 2020 published

Regulatory pressrelease

Hørsholm, Denmark, May 20, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company's interim report for the first quarter 2020 is published. The interim report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion Announces Bavarian Nordic Enters Agreement with AdaptVac to Advance the COVID-19 Vaccine Program

Regulatory pressrelease

Hørsholm, Denmark, May 06, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that its joint venture AdaptVac has entered into an exclusive head of terms agreement with Bavarian Nordic, a global leader in the development, manufacture and commercialization of life-saving vaccines, to license the COVID-19 vaccine. The parties seek to enter into the final…

Read more

ExpreS2ion - Annual report for 2019 published

Regulatory pressrelease

Hørsholm, Denmark, May 05, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company's annual report for the financial year 2019 is published. The annual report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com).

Read more

ExpreS2ion announces last part of loan conversion and new loan facility

Regulatory pressrelease

Hørsholm, Denmark, May 04, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that SEK 1.75 million (excluding accrued interest) of the loan provided by Modelio Equity AB (https://news.cision.com/expres2ion-biotechnologies/r/expres-2-ion-secures-sek-8-million-in-bridge-financing-to-facilitate-further-growth,c2933530) (“Modelio”) will be converted into new shares at a price of approximately SEK 9.06 (corresponding to a 10% discount off the last 15 trading days volume-weighted average…

Read more

ExpreS2ion announces supporting an advantageous COVID-19 diagnostic antibody development project

Non-regulatory pressrelease

Hørsholm, Denmark, May 4, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that its SARS-CoV-2 antigen is being applied across multiple research and development projects, including an on-going diagnostic antibody test program that Rigshospitalet, University of Copenhagen and Novo Nordisk jointly develop to support the diagnosis…

Read more

ExpreS2ion announces selection of AGC Biologics as manufacturing partner for the COVID-19 vaccine and provides update to the program

Regulatory pressrelease

Hørsholm, Denmark, April 24, 2020 – Today, ExpreS[2]ion Biotechnologies ApS (“ExpreS[2]ion”), a fully owned subsidiary of ExpreS[2]ion Biotech Holding AB, announces that its joint venture AdaptVac and AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals enters into a partnership for the scale-up and cGMP manufacture of the COVID-19 vaccine developed by…

Read more

Notice to Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)

Regulatory pressrelease

The shareholders of ExpreS2ion Biotech Holding AB (publ), 559033-3729, are hereby invited to attend the Annual General Meeting on Tuesday, May 26, 2020, at 4:00 p.m. at Clarion Grand Hotel, Stortorget 8, in Helsingborg.

Read more

ExpreS2ion announces loan conversion

Regulatory pressrelease

Hørsholm, Denmark, April 21, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that SEK 1.75 million (excluding accrued interest) of the loan provided by Modelio Equity AB (https://news.cision.com/expres2ion-biotechnologies/r/expres-2-ion-secures-sek-8-million-in-bridge-financing-to-facilitate-further-growth,c2933530) will be converted into new shares at a price of SEK 6.4925 (corresponding to the last 15 trading days volume-weighted average share price).

Read more

ExpreS2ion’s CSO Dr. Wian de Jongh co-signs WHO-sanctioned statement from 83 COVID-19 vaccine researchers

Non-regulatory pressrelease

Hørsholm, Denmark, April 15, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the company’s Chief Scientific Officer Dr. Wian de Jongh is a co-signer of a WHO statement from 83 COVID-19 vaccine researchers from all over the world. The statement encourages everyone to follow recommendations…

Read more

ExpreS2ion announces 6.7 MSEK EU Horizon 2020 grant for the development of a unique influenza vaccine

Regulatory pressrelease

Hørsholm, Denmark, March 31, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the international next-generation influenza vaccine consortium INDIGO, led by the University of Amsterdam with ExpreS2ion as a participating member, has been awarded a 10.0 MEUR Horizon 2020 grant from the EU. ExpreS2ion’s participation…

Read more

ExpreS2ion rearranges its event schedule due to Coronavirus restrictions

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is rearranging its recently communicated event schedule due to events changes as a results of COVID-19-related travel restrictions. The company’s main priority during this time is to progress rapidly with the ongoing EU Horizon 2020-funded COVID-19 vaccine development project together with the rest of the consortium…

Read more

ExpreS2ion announces EU grant award for the COVID-19 vaccine development programme

Regulatory pressrelease

Hørsholm, Denmark, March 6, 2020 – Today, ExpreS[2]ion Biotechnologies ApS (“ExpreS[2]ion”), a fully owned subsidiary of ExpreS[2]ion Biotech Holding AB, announces that the consortium has been awarded an EU Horizon 2020 grant for the COVID-19 (SARS-CoV-2) Coronavirus vaccine development programme. The award funding amounts to 2,7 MEUR (28MSEK), of which ExpreS[2]ion directly is funded with…

Read more

ExpreS2ion will present its ExpreS2 platform and pipeline at several key events in March and April 2020

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate at several key events in March and April, including Aktiespararna’s Aktiedagen, March 16 in Stockholm, Sweden, BIO-Europe Spring, March 23-25 in Paris, France, and World Vaccine Congress, April 6-8 in Washington, DC, USA.

Read more

ExpreS2ion Biotech Holding AB: Publication of Year-End Report 2019

Regulatory pressrelease

Hørsholm, Denmark, February 26, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes its Year-End Report for the period January – December 2019. The report is available as an attached document to this press release and on the company’s website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion will be allocated approximately SEK 9,6 million through the redemption of warrants and at the same time converts part of loan

Regulatory pressrelease

Hørsholm, Denmark, February 26, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company has received written confirmation from warrant holders that these parties will exercise all of their warrants of series TO 3. ExpreS2ion will thereby be allocated approximately SEK 9.6 million before issue costs. In connection with this share issue SEK…

Read more

ExpreS2ions Year-End Report for 2019 will be published today

Regulatory pressrelease

Hørsholm, Denmark, February 26, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company’s Year-End Report for 2019 will be published today, as the report is finalized earlier than planned. Previous date for publication of the report was on Friday, the 28[th] of February, 2020.

Read more

ExpreS2ion Signs Option to License Agreement with AdaptVac Regarding Unique Breast Cancer Vaccine

Regulatory pressrelease

Hørsholm, Denmark, February 26, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the company has signed an Option to License Agreement (“Agreement”) with AdaptVac ApS (“AdaptVac”) whereby ExpreS2ion may call an option to exclusively license in AV001 (HER2-cVLP), a preclinical-stage novel breast cancer vaccine candidate,…

Read more

ExpreS2ion’s joint venture AdaptVac receives Eurostars grant to further support its HER2 vaccine project AV001

Regulatory pressrelease

Hørsholm, Denmark, February 25, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that a consortium led by the company’s joint venture AdaptVac has been awarded a 0.6 MEUR Eurostars grant, of which AdaptVac directly receives 1.3 MDKK (1.8 MSEK). The grant will support pre-clinical safety and…

Read more

ExpreS2ion to lead European COVID-19 vaccine consortium for rapid clinical development

Regulatory pressrelease

Hørsholm, Denmark, February 24, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the company will lead a consortium of European expert entities in applying for the EU Horizon 2020 and the Coalition for Epidemic Preparedness Innovations (CEPI) grant calls for COVID-19 (SARS-CoV-2) Coronavirus vaccine development.…

Read more

ExpreS2ion announces initiation of a Wuhan Coronavirus vaccine program

Regulatory pressrelease

Hørsholm, Denmark, February 6, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces the initiation of a Wuhan Coronavirus (2019-nCoV) vaccine program. ExpreS2ion will produce viral antigens needed for diagnostics and vaccine research, focused on internal vaccine development efforts. The program’s first stage has a timeline of…

Read more

ExpreS2ion’s CEO in interview on 2019 and the company’s new way forward with a stronger pipeline focus

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) publishes an interview with newly appointed CEO Bent Frandsen upon shareholder request. The company’s new way forward with Bent at the helm will include a much stronger focus on building a pipeline portfolio with assets developed in the ExpreS2 platform.

Read more

ExpreS2ion is streamlining its market communication with English as primary language

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that the company has chosen to streamline its market communication, and will only provide press releases and interim reports in English. ExpreS2ion’s annual report will continue to be published in both Swedish and English. 

Read more

ExpreS2ion’s joint venture AdaptVac granted US patent for its core platform technology

Regulatory pressrelease

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture company AdaptVac ApS (“AdaptVac”) has been granted a US patent covering its core technology platform. This confirms the overall patentability and proprietary protection of AdaptVac’s entire pipeline and future projects. In particular, this consolidates the position of the AV001 breast cancer vaccine for which a…

Read more

ExpreS2ion appoints Bent U. Frandsen as Chief Executive Officer

Regulatory pressrelease

ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion”) today announces that the Company’s Board of Directors has appointed Bent U. Frandsen as the new Chief Executive Officer of ExpreS[2]ion, succeeding Steen Klysner as of today 20 December, 2019. Bent has been with ExpreS[2]ion since March 2016 and has served as the Company’s Chief Business Officer since August 2018.

Read more

ExpreS2ion has been awarded SEK 2.7 million for continued development of two malaria vaccine candidates

Regulatory pressrelease

ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion”) announces that the Company has been awarded SEK 2.7 million as part of the Horizon 2020-funded OptiMalVax grant consortium, led by Jenner Institute at the University of Oxford, to establish monoclonal Drosophila S2 cell banks for two new malaria vaccine candidates. One targets blood-stage malaria, potentially in combination with the…

Read more

ExpreS2ion Biotech Holding AB: Publication of interim report for January – September 2019

Regulatory pressrelease

ExpreS[2]ion Biotech Holding AB (“ExpreS[2]ion”) hereby publishes its interim report for the period January – September 2019. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.

Read more

Breakthrough: ExpreS2ion launches first unique cell line for enhanced efficacy of vaccines and immunotherapy

Regulatory pressrelease

After several years of research and development, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces the launch of a new tailormade S2 cell line, HighMan-S2™. This is the first member of ExpreS2ion’s new functionally modified S2 product line, GlycoX-S2™, which utilises and expands the advantages of the ExpreS2 platform.

Read more

ExpreS2ion’s joint venture AdaptVac receives Danish InnoBooster grant of 1.2 MSEK for for breast cancer studies in dogs

Regulatory pressrelease

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces today that its joint venture company AdaptVac ApS (“AdaptVac”) has been awarded an InnoBooster grant by the Danish Innovation Foundation worth 0.8 MDKK (approx. 1.2 MSEK). The grant provides further resources for the development of a safe and effective treatment for dogs diagnosed with DER2+ cancer. In addition to…

Read more

ExpreS 2 ion secures SEK 8 million in bridge financing to facilitate further growth

Regulatory pressrelease

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that the Company is increasing its working capital by securing a combination of a bridge loan and a loan facility of up to SEK 8 million in total. This will enable ExpreS2ion to further expand its business activities in line with the growth numbers reported for Q1 and Q2…

Read more

ExpreS2ion signs commercial license agreement with ABIVAX for using the ExpreS2 platform in their Ebola program

Horsholm, Denmark, April 20, 2017 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”), announces that the fully owned subsidiary ExpreS2ion Biotechnologies […]

ExpreS2ion files joint-patent on the production of an improved malaria vaccine with the Walter and Eliza Hall Institute of Medical Research

Horsholm, Denmark, April 6, 2017 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”), announces that the fully owned subsidiary ExpreS2ion Biotechnologies […]

ExpreS2ion Biotech Holding AB announces that the OptiFemVac Consortium has received final Eurostars approval of its grant application for development of a novel Zika vaccine

Hørsholm, Denmark, March 30, 2017 – Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS […]

ExpreS2ion’s Licensee, VaxInnate, is Winding Down Operations

Horsholm, Denmark, February 9, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, […]

ExpreS2ion announces the initial approval of a Eurostars grant application, OptiFemVac, with main focus on the development of a Zika vaccine

Horsholm, Denmark, January 23, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, […]

ExpreS2ion and ABIVAX announce development collaboration on the Ebola prophylaxis and treatment program, ABX544

Horsholm, Denmark and Paris, France, December 12, 2016 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion […]

ExpreS2ion announces the initiation of a Phase I/IIa clinical trial for a new blood-stage malaria vaccine

Horsholm, Denmark, October 18, 2016 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its collaboration partner, the Jenner Institute […]

ExpreS2ion and VaxInnate Sign Research License Agreement

Horsholm, Denmark, September 20, 2016 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”), and VaxInnate Corporation (“VaxInnate”) announce that they have […]

ExpreS2ion Biotech Holding AB: Första dag för handel på Nasdaq Stockholm First North

Idag, den 29 juli 2016, inleds handeln i ExpreS2ion Biotech Holding AB:s (”ExpreS2ion”) aktier på Nasdaq Stockholm First North. Handel […]

ExpreS2ion Biotech announces clinical trial update for the PamVac (Placental Malaria Vaccine) phase I study

ExpreS2ion Biotech announces the second successful evaluation of safety by the independent safety monitoring board for the phase Ia clinical […]

ExpreS2ion Biotech Holding AB approved for listing on Nasdaq Stockholm First North

ExpreS2ion Biotech Holding AB (“ExpreS2ion “) announces that the Company has met the requirements for listing on Nasdaq Stockholm First […]

ExpreS2ion Biotech Holding AB: Listing process delayed

ExpreS2ion Biotech Holding AB herby announces that the listing process at Nasdaq Stockholm First North has been delayed. The company […]

ExpreS2ion Biotech Holding AB’s initial public offering oversubscribed

The 22 June 2016 the subscription period in ExpreS2ion Biotech Holding AB’s (”ExpreS2ion”) initial public offering (”IPO”) of shares at […]

ExpreS2ion Biotech Announces Grant of US Patent

Today, June 21, 2016, ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion Biotech”) announce that its fundamental […]

Today the subscription period of ExpreS2ion Biotech Holding AB’s Initial Public Offering begins

Today, June 8, 2016, the subscription period commences regarding ExpreS2ion Biotech Holding AB’s (“ExpreS2ion”) initial public offering before the planned […]

ExpreS2ion Biotech Holding AB publishes memorandum in advance of the Initial Public Offering

ExpreS2ion Biotech Holding AB (”ExpreS2ion”) hereby publishes the memorandum for the Initial Public Offering which the company plans to commence […]

ExpreS2ion Biotech Holding AB is planning an Initial Public Offering and listing on Nasdaq Stockholm First North

ExpreS2ion Biotech Holding AB (”ExpreS2ion”) hereby announces on May 26th 2016 that the company is planning an Initial Public Offering […]